Charles E Rutter1, James B Yu2, Lynn D Wilson2, Henry S Park2. 1. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut; Yale Cancer Center, New Haven, Connecticut. Electronic address: charles.rutter@yale.edu. 2. Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut; Yale Cancer Center, New Haven, Connecticut.
Abstract
PURPOSE: To characterize temporal trends in the application of various bone metastasis fractionations within the United States during the past decade, using the National Cancer Data Base; the primary aim was to determine whether clinical practice in the United States has changed over time to reflect the published randomized evidence and the growing movement for value-based treatment decisions. PATIENTS AND METHODS: The National Cancer Data Base was used to identify patients treated to osseous metastases from breast, prostate, and lung cancer. Utilization of single-fraction versus multiple-fraction radiation therapy was compared according to demographic, disease-related, and health care system details. RESULTS: We included 24,992 patients treated during the period 2005-2011 for bone metastases. Among patients treated to non-spinal/vertebral sites (n=9011), 4.7% received 8 Gy in 1 fraction, whereas 95.3% received multiple-fraction treatment. Over time the proportion of patients receiving a single fraction of 8 Gy increased (from 3.4% in 2005 to 7.5% in 2011). Numerous independent predictors of single-fraction treatment were identified, including older age, farther travel distance for treatment, academic treatment facility, and non-private health insurance (P<.05). CONCLUSIONS: Single-fraction palliative radiation therapy regimens are significantly underutilized in current practice in the United States. Further efforts are needed to address this issue, such that evidence-based and cost-conscious care becomes more commonplace.
PURPOSE: To characterize temporal trends in the application of various bone metastasis fractionations within the United States during the past decade, using the National Cancer Data Base; the primary aim was to determine whether clinical practice in the United States has changed over time to reflect the published randomized evidence and the growing movement for value-based treatment decisions. PATIENTS AND METHODS: The National Cancer Data Base was used to identify patients treated to osseous metastases from breast, prostate, and lung cancer. Utilization of single-fraction versus multiple-fraction radiation therapy was compared according to demographic, disease-related, and health care system details. RESULTS: We included 24,992 patients treated during the period 2005-2011 for bone metastases. Among patients treated to non-spinal/vertebral sites (n=9011), 4.7% received 8 Gy in 1 fraction, whereas 95.3% received multiple-fraction treatment. Over time the proportion of patients receiving a single fraction of 8 Gy increased (from 3.4% in 2005 to 7.5% in 2011). Numerous independent predictors of single-fraction treatment were identified, including older age, farther travel distance for treatment, academic treatment facility, and non-private health insurance (P<.05). CONCLUSIONS: Single-fraction palliative radiation therapy regimens are significantly underutilized in current practice in the United States. Further efforts are needed to address this issue, such that evidence-based and cost-conscious care becomes more commonplace.
Authors: Sanders Chang; Peter May; Nathan E Goldstein; Juan Wisnivesky; Kenneth Rosenzweig; R Sean Morrison; Kavita V Dharmarajan Journal: J Palliat Med Date: 2017-11-30 Impact factor: 2.947
Authors: James B Yu; Craig E Pollack; Jeph Herrin; Weiwei Zhu; Pamela R Soulos; Xiao Xu; Cary P Gross Journal: Am J Clin Oncol Date: 2019-06 Impact factor: 2.339
Authors: William A Stokes; Diana Abbott; Andy Phan; David Raben; Ryan M Lanning; Sana D Karam Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-06 Impact factor: 7.038
Authors: Benjamin W Fischer-Valuck; Brian C Baumann; Anthony Apicelli; Yuan James Rao; Michael Roach; Mackenzie Daly; Maria C Dans; Patrick White; Jessika Contreras; Lauren Henke; Hiram Gay; Jeff M Michalski; Christopher Abraham Journal: Cancer Med Date: 2018-08-17 Impact factor: 4.452